This week, the U.S. Food and Drug Administration (FDA) issued Warning Letters that effectively declare that the presence of cannabidiol (CBD) as an inactive ingredient in topical over-the-counter (OTC) drug products is a ...more
Near the end of 2020, in mid-December, the Federal Trade Commission (FTC) launched what it referred to as “Operation CBDeceit,” a law enforcement sweep challenging allegedly unproven representations that CBD products could...more
3/12/2021
/ Advertising ,
Alzheimer's ,
Attorney General ,
Cancer ,
Cannabidiol (CBD) oil ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Class Action ,
Coronavirus/COVID-19 ,
Criminal Prosecution ,
False Advertising ,
FDA Warning Letters ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
FTC Act ,
Health Claims ,
Labeling ,
Marketing ,
Scientific Evidence
It is relatively easy for investors to make investments in cannabis companies. Given the risks, however, they would be well-advised to have an exit plan in the event their investment does not live up to their expectations....more
8/14/2020
/ Anti-Money Laundering ,
Cannabidiol (CBD) oil ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Controlled Substances ,
Controlled Substances Act ,
Exit Strategies ,
Farm Bill ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Fiduciary Duty ,
Food and Drug Administration (FDA) ,
Hemp ,
Investment Opportunities ,
Investors ,
Marijuana ,
Marijuana Cultivation ,
Marijuana Related Businesses ,
Money Laundering ,
SAFE Act ,
State and Local Government